APA (7th ed.) Citation

LM, S., L, S., AJ, M., A, N., A, C., T, M., . . . A, B. (2025). Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER). NPJ breast cancer, 11(1), 2. https://doi.org/10.1038/s41523-024-00708-5

Chicago Style (17th ed.) Citation

LM, Spring, et al. "Adjuvant Endocrine Therapy with Cyclin-dependent Kinase 4/6 Inhibitor, Ribociclib, for Localized Hormone Receptor-positive/HER2- Breast Cancer (LEADER)." NPJ Breast Cancer 11, no. 1 (2025): 2. https://doi.org/10.1038/s41523-024-00708-5.

MLA (9th ed.) Citation

LM, Spring, et al. "Adjuvant Endocrine Therapy with Cyclin-dependent Kinase 4/6 Inhibitor, Ribociclib, for Localized Hormone Receptor-positive/HER2- Breast Cancer (LEADER)." NPJ Breast Cancer, vol. 11, no. 1, 2025, p. 2, https://doi.org/10.1038/s41523-024-00708-5.